Alto Neuroscience (ANRO) Invested Capital (2023 - 2026)

Alto Neuroscience (ANRO) posted Invested Capital of $2.1 million for Q1 2026, up 265.13% sequentially from $585000.0 in Q4 2025.

Analysis

Alto Neuroscience (ANRO) Invested Capital (2023 - 2026) Analysis & Trends

Alto Neuroscience has reported Invested Capital for 3 years, with the latest figure at $2.1 million in Q1 2026.

Quarterly Invested Capital changed N/A year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 53.46% YoY) and the FY2025 annual result came in at $585000.0, changed N/A from the prior year.
Invested Capital grew to $2.1 million in Q1 2026 per ANRO's latest filing, from $585000.0 in the prior quarter.
Over five years, Invested Capital peaked at $3.5 million in Q3 2024 and troughed at $585000.0 in Q4 2025.
A 3-year average of $1.9 million and a median of $2.1 million in 2026 frame the typical range for Invested Capital.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Alto Neuroscience	1.52 Bn	1.52 Bn	-	235.44 Mn

Historic Data

Download Data